Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR35579818

— · A

03f9b81b-5f2f-5f41-8762-d1267b1d83a2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.650
  • UV_RESPONSE_DN+0.450
  • ANGIOGENESIS+0.420
  • NOTCH_SIGNALING+0.370
  • INTERFERON_ALPHA_RESPONSE+0.360
  • MYOGENESIS+0.360
  • COAGULATION+0.350
  • TGF_BETA_SIGNALING+0.350
  • WNT_BETA_CATENIN_SIGNALING+0.340
  • APICAL_JUNCTION+0.330

Top 10 suppressed

  • MYC_TARGETS_V1-0.640
  • E2F_TARGETS-0.620
  • OXIDATIVE_PHOSPHORYLATION-0.560
  • G2M_CHECKPOINT-0.530
  • MYC_TARGETS_V2-0.490
  • MTORC1_SIGNALING-0.460
  • UNFOLDED_PROTEIN_RESPONSE-0.400
  • DNA_REPAIR-0.390
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
  • PROTEIN_SECRETION-0.370

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-E2-A1IJ-01A-11R-A144-07
breast-umap@18
—A0.934
2TCGA-AC-A3HN-01A-11R-A213-07
breast-umap@18
—A0.928
3TCGA-50-8459-01A-11R-2326-07
lung-landscapes@6
—cohortMD20.928
420020074.LumA
breast-umap@18
—A0.926
540b98f15-43cb-426b-880c-951a4b28c3e2
colon-landscapes@1
——0.920
6TCGA-AC-A6IV-01A-12R-A33J-07
breast-umap@18
—A0.914
7SRR1516085
bladder-landscape@3
——0.913
8SRR2771286
melanoma-umap@29
——0.913
9SRR5088925
melanoma-umap@29
——0.912
10BSR_12_0273_A5_S86
breast-umap@18
—A0.910

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.650Inavolisib— uncovered
UV_RESPONSE_DN0.450Inavolisib— uncovered
ANGIOGENESIS0.420Remibrutinib— uncovered
NOTCH_SIGNALING0.370Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.360Inavolisib— uncovered
MYOGENESIS0.360Inavolisib— uncovered
COAGULATION0.350Binimetinib— uncovered
TGF_BETA_SIGNALING0.350Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.340Inavolisib— uncovered
APICAL_JUNCTION0.330Inavolisib— uncovered
HEDGEHOG_SIGNALING0.330Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.330Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.290Idelalisib— uncovered
IL2_STAT5_SIGNALING0.270Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.270Inavolisib— uncovered
KRAS_SIGNALING_UP0.270Inavolisib— uncovered
ALLOGRAFT_REJECTION0.250Idelalisib— uncovered
APICAL_SURFACE0.240Temsirolimus— uncovered
COMPLEMENT0.230Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.120Inavolisib— uncovered